8,801 Becton, Dickinson and Company $BDX Shares Purchased by Keybank National Association OH

Keybank National Association OH boosted its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 63.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,594 shares of the medical instruments supplier’s stock after buying an additional 8,801 shares during the period. Keybank National Association OH’s holdings in Becton, Dickinson and Company were worth $4,044,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Waterhouse Canada Inc. lifted its holdings in shares of Becton, Dickinson and Company by 17.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock worth $14,715,000 after acquiring an additional 14,077 shares during the last quarter. Northside Capital Management LLC increased its holdings in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after purchasing an additional 9,494 shares during the last quarter. Capital Analysts LLC increased its holdings in Becton, Dickinson and Company by 7.5% in the 2nd quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock valued at $12,651,000 after purchasing an additional 5,828 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Becton, Dickinson and Company by 35.0% in the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC purchased a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $3,353,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on BDX. TD Cowen upped their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Barclays boosted their price objective on Becton, Dickinson and Company from $165.00 to $195.00 and gave the company an “underweight” rating in a report on Tuesday, November 10th. Piper Sandler increased their target price on Becton, Dickinson and Company from $175.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, November 6th. Finally, Royal Bank Of Canada raised their target price on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $197.47.

Get Our Latest Stock Report on BDX

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 2,993 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $23,134,230. This represents a 2.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 3,310 shares of company stock valued at $688,650. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0%

Shares of BDX stock opened at $217.95 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. The stock has a market capitalization of $60.05 billion, a P/E ratio of 52.64, a price-to-earnings-growth ratio of 3.65 and a beta of 0.22. The company has a 50 day moving average price of $190.90 and a 200 day moving average price of $170.56. Becton, Dickinson and Company has a fifty-two week low of $140.11 and a fifty-two week high of $219.78.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.96 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 13.21 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be paid a $1.06 dividend. This represents a $4.24 annualized dividend and a dividend yield of 1.9%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s payout ratio is presently 101.45%.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Thursday, November 5th that permits the company to buy back 10,000,000 shares. This buyback authorization permits the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.